Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:
”Publication Alert
Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Health Science Reports | Volume 9, Issue 1
(e71702)
Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI
Published: 29 December 2025
This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.
• Read here.
Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.
Feedback and discussions are most welcome!”
Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 6, 2026, 16:43Beth Shirley: Xylitol Consumption Increases Platelet Reactivity and Cardiovascular Risk
-
Oct 6, 2026, 16:37Jared Rice: What Sets the Transfusion Threshold in Anemia of Prematurity?
-
Oct 6, 2026, 16:30Thirunavukkarasu Angappan: Immunoglobulin Decides How Much Plasma Gets Collected
-
Oct 6, 2026, 16:18Gemma Davies: New CMML Research Selected for Presentation at the 68th ASH Annual Meeting
-
Oct 6, 2026, 16:03Professor Csongor Kiss Receives the Kálmán Laki Prize – Hungarian Society of Thrombosis and Haemostasis
-
Oct 6, 2026, 15:52Mark Kheifets: A Massive Stent Thrombosis Requiring Aspiration Thrombectomy
-
Oct 6, 2026, 15:40Joseph Aslan։ Targeting Mitochondrial Permeability Transition To Reduce Platelet Thrombogenicity
-
Oct 6, 2026, 15:36Nominations Open for ISTH Outstanding Mentor Awards – ISTH
-
Oct 6, 2026, 15:17Walaa Obaid: How Warfarin Went From Poison To Medicine